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Abstract
Background: The increased mortality in HCV-infected individuals partly stems from viral damage to the liver and partly from
risk-taking behaviours. We examined mortality in patients who cleared their HCV-infection, comparing it to that of the
general population. We also addressed the question whether prognosis differed according to age, substance abuse (alcohol
abuse and injection drug use) and comorbidity.
Methodology/Principal Findings: Patients with cleared HCV-infection were categorized into one of 8 groups according to
age (20–39 years or 40–69 years) and patient characteristics (no substance abuse/no comorbidity; substance abuse/no
comorbidity; no substance abuse/comorbidity; and substance abuse/comorbidity). For each patient, 4 age- and gender-
matched individuals without substance abuse or comorbidity were selected from the general population, comprising a total
of 8 comparison cohorts. We analyzed 10-year survival and used stratified Cox Regression analysis to compute mortality rate
ratios (MRRs), comparing mortality between the 8 patient groups and the comparison cohorts, adjusting for personal
income. Among patients without substance abuse or comorbidity, those aged 40–69 years had the same mortality as the
comparison cohort (10-year survival: 95% (95% confidence interval [CI]: 93%–97%), MRR: 1.3 (95% CI: 0.8–2.3)), whereas
those aged 20–39 years had higher mortality than the comparison cohort (10-year survival: 93% versus 99%, MRR: 5.7 (95%
CI: 2.3–14.0). For both age categories, substance abuse and comorbidity decreased survival and increased MRRs. Patients
aged 40–69 years with substance abuse and comorbidity suffered from substantial mortality (MRR: 12.5 (95% CI: 5.1–30.6)).
Conclusions: Mortality in patients aged 40–69 years with cleared HCV-infection is comparable to individuals without HCV,
provided they have no substance abuse or comorbidity. Any substance abuse and/or comorbidity not captured in the
registries used for our study could explain the increased mortality in patients aged 20–39 years without documented
substance abuse or comorbidity.
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Introduction
Large cohort studies have documented 2- to 18-fold higher
mortality among HCV-infected patients compared to the general
population [1–4]. Increasingly effective treatments provide
optimism about improved life expectancy in HCV-infected
patients [5,6]. However, they are at elevated risk of both liver-
related death and of unnatural causes of death/drug-related death
[1,3], attributable to a high prevalence of lifestyle-related risk
factors (alcohol abuse and injection drug use (IDU)) [3]. Thus,
HCV-infected patients may remain at increased risk of death even
after clearing the virus. Estimates of absolute mortality risk are
needed for these patients, disaggregated by presence or absence of
comorbidity, alcohol abuse and IDU. To date such estimates have
not been reported.
We therefore conducted a nationwide cohort study of patients
with cleared HCV-infection (without HIV), estimating 5- and 10-
year risks of death compared to that of an age- and gender
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22476matched comparison cohort without HIV, comorbidity or
substance abuse (alcohol abuse or IDU).
Patients were categorized into one of 8 groups according to age
(20–39 years or 40–69 years) and characteristics at time of
diagnosis, i.e., those with no substance abuse or comorbidity; those
with substance abuse; those with comorbidity; and those with
substance abuse and comorbidity. Five- and 10-year mortality in
each of these subgroups was estimated and compared to that of
corresponding subgroups in the comparison cohort.
Materials and Methods
Setting
Denmark has a population of 5.5 million persons [7] and an
estimated population of chronically HCV-infected patients of
15.000 (prevalence of 0.3) [8]. Medical care, including antiviral
treatment, is provided free of charge to all HCV-infected residents.
It has been estimated that only 2% of this patient population has
been treated with interferon [9]. Suboptimal screening activity and
ineffective prevention and management strategies could explain
this rather low percentage [9]. However, for HCV-infected
patients referred for evaluation in one of the 15 centres specialised
in treating viral hepatitis in Denmark, the 5-year probability of
being treated with interferon is 33% (95% confidence interval (CI):
28%–38%) [10].
Data sources
We used the unique 10-digit civil registration number assigned
to all individuals in Denmark to link individual-level data from the
following data sources [11]:
Danish HCV cohort (DANVIR). HCV RNA negative
patients were identified from the DANVIR cohort, a prospective
research cohort consisting of all patients tested for hepatitis B or
HCV-infection in 14 of the 18 Danish laboratories that perform
such testing [3,12,13]. In total, 13,005 patients are registered in
the DANVIR cohort during the period between 1
st January 1991
and 1
st January 2007. The number under observation has
increased during the study period from 781 at 1
st January 1995,
4139 at 1
st January 2000 and 9789 at 1
st January 2005 (0.2% of
the Danish population). Enrolments increased from approximately
200/year the first 5 years until it peaked in 2004 (1807
enrolments). Patients are included the first date of a test
indicating HCV-exposure (a positive test for HCV-antibodies
and/or HCV RNA). Many, but not all patients have both a
positive test for HCV antibodies and an available test for HCV
RNA, enabling a determination of whether or not they have
cleared their HCV-infection [13]. Results of genotype test are
available only for few patients.
The Danish National Hospital Registry (DNHR). The
DNHR, established in 1977, records all hospital admissions to
non-psychiatric hospitals in Denmark. Data from outpatient and
emergency department visits were added starting in 1995. Registry
records for each medical contact include dates of admission and
discharge and up to 20 discharge diagnoses, coded according to
the International Classification of Diseases, 8th revision (ICD-8) through
1993 and 10th revision (ICD-10) from 1994 onward. Diagnostic
codes are assigned by physicians [14]. We used this registry to
ascertain HIV status, alcohol abuse and IDU. In 2005, DNHR
recorded 1,205,000 discharges and 6,336,000 outpatient visits
[15]. Of the 13,005 patients in DANVIR, 12,150 patients (93%)
had one or more contact registered in DNHR before, on or after
the date of inclusion in DANVIR.
The Registry of Drug Abusers Undergoing Treatment
(RDT). The RDT, run by the National Board of Health, has
registered all individuals in Denmark receiving treatment for drug
addiction since 1996 [16]. Treatment of drug addiction in
Denmark is restricted to referral centers, which must supply data
to the RDT in order to obtain funding. The RDT registers the
main drug used (opioids, hashish or centrally acting drugs),
whether patients are treated as outpatients or inpatients and
whether patients receive substitution therapy or not. In 2006,
13.441 patients received treatment and were registered in RDT
with 5426 initiating treatment in 2006 and the remainder (8015)
initiating treatment before 2006. Of the 5426 initiating treatment
in 2006, 1329 had not previously been treated. Of the 13.005
patients in DANVIR, 6143 (47%) were registered in RDT before,
on or after the date of inclusion in DANVIR [17]. We also
ascertained IDU from this registry.
The Danish Civil Registration System (CRS). The CRS,
established in 1968, updates the vital status of all Danish citizens
on a daily basis, including the date of death or emigration. The
CRS also stores information on municipality of residence and
migration for all Danish residents [11]. As of November 2005, the
CRS included information on 8.2 million persons, of which 5.4
million were alive and living in Denmark. The cornerstone of
CRS’s extreme completeness in terms of vital status (including
emi- and immigration) is the civil registration number used by all
national registries as well as Danish legislation, according to which
all residents in Denmark are obliged to inform the authorities
about any change of permanent address within 5 days [11,18,19].
Failure to supply this information will results in loss of all of
benefits provided by the state - therefore it is very unlikely that this
mandatory information is not reported [19].
The Integrated Database for Labour Market Research
(IDA). The IDA, established by Statistics Denmark in 1980,
records individual-level data on the annual personal income of all
Danish citizens [20].
Danish Registry of Causes of Death (DRCD). The DRCD
contains information extracted from all Danish death certificates
since 1943 [21]. Whenever a Danish citizen dies, the attending
physician must report the cause of death. Up to 4 diagnoses can be
specified to describe the chain of events leading to death. Causes of
deaths occurring during the study period were coded according to
ICD-10.
Study population
We focused on patients in DANVIR, who were a) diagnosed
with a positive test for HCV antibodies and who subsequently
tested negative for HCV RNA (the date of the latter test was used
as the index date), b) age 20 years or older on the index date and c)
not coinfected with HIV. Patients from DANVIR fulfilling these
criteria from 1 January 1996 to 31 December 2006 were included
in the study. In this way, 2320 of the 13005 patients registered in
DANVIR (18%) were included in the present study. For each of
these 2320 patient, 4 age- and gender-matched individuals without
HCV-infection were identified from the CRS (N=9280). These
individuals, who served as the comparison cohort, had to be free of
HIV infection, alcohol abuse, IDU and comorbidity, as defined
below.
Information on study subjects
Comorbidity was measured based on the Charlson Comorbidity
Index (CCI) score derived from diagnoses registered in the DNRP
before the index date [22,23]. The intention with the creation of the
CCI was to develop a prognostic score based on comorbid
conditions, which could predict (short term) mortality in longitu-
dinal studies [22]. The score has been validated a number of times
[23–25] and has proved capable of also predicting long-term
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of diseases, with the sum of individual scores serving as a measure of
patients’ overall comorbidity. We identifiedcomorbid diseases using
the ICD-10 codes provided by Quan et al. [25] (matching ICD-8
codes to ICD-10 codes as closely as possible [Appendix 3]) and
categorized patients as having comorbidity or not (yes/no). Liver
diseases were excluded from the CCI for the purposes of the present
study (Appendix 3).
Alcohol abuse, IDU and HIV status were ascertained from the
DNRP and RDT, as specified in the Appendix 1 and previously
described [3]. We defined substance abuse as having a diagnosis of
alcohol abuse and/or IDU as of the index date.
Yearly income was ascertained for the calendar year preceding
HCV RNA assessment, characterized as 0%–49%, 50%–99% or
100+% of the average income for all Danish citizens of the same
age and gender in the same calendar year.
Cause of death. Based on the diagnosis listed as the primary
cause of death, we categorized deaths into one of 3 categories:
liver-related deaths, non-liver-related natural deaths or unnatural
deaths (see Appendix 2 for details).
Statistical analysis
Study outcomes were time to all-cause mortality and time to
cause-specific mortality. Time at risk was calculated from the
index date until death, emigration or 31 December 2006,
whichever came first. We analyzed individuals aged 20–39 years
and 40–69 years separately, as younger HCV-infected patients are
at particularly high risk of death compared to the general
population [3]. Mortality was analyzed using Kaplan-Meier
survival analyses. We used stratified Cox regression models
(according to the matched design) to analyze whether patients
with cleared HCV-infection had higher mortality than the
comparison cohort. We then reran the Cox regression models
with adjustment for personal income, categorized as 0%–49%,
50%–99% and 100+% of national average income. We analyzed
cause-specific mortality in the same way as for overall mortality,
but without adjusting for income (due to the small number of
events in each category).
We then further subdivided the 2 subgroups of patients with
cleared HCV-infection (i.e., those aged 20–39 years and those aged
40–69 years) according to their characteristics (patients with no
comorbidity or substance abuse; patients with substance abuse;
patients with comorbidity; and patients with comorbidity and
substance abuse), resulting in a total of 8 subgroups of patients
with cleared HCV-infection. The analyses of overall mortality
were then repeated for each of these subgroups in order to identify
patients with a particularly good or bad prognosis.
Ethics
Since the study is entirely based on data from national registries
and clinical databases, there was according to Danish law no
request for an ethical permission (Denmark has no Institutional
review boards). The study was approved by Danish Data
Protection Agency.
Results
Descriptive data
From the DANVIR cohort we identified 2,320 patients with
cleared HCV-infection. The median age was 41 years at study
inclusion. Characteristics of these patients and the comparison
cohort are provided in Table 1. 47% of the patients were IDU –
with more IDUs among the younger than among the older
patients. 11% were alcohol abusers (current or former) and 16%
had comorbidity. There were more patients with alcohol abuse
and comorbidity among older patients than among the younger
patients. Further, among those patients with comorbidity, the level
of comorbidity was higher among older than younger patients.
Although not included in our definition of comorbidity, more
patients aged 40–69 years than patients aged 20–39 years had liver
disease according to the CCI. Income was low in both the younger
and the older age categories with few individuals having an income
above national average for same sex and gender.
Mortality
Patients with cleared HCV-infection had higher mortality than
the comparison cohort; 10-year survival was 87% (95% CI: 84–
90%) in patients aged 20–39 and 80% (95% CI: 76–85%) in those
aged 40–69 years (Figure 1). Patients with substance abuse (alcohol
abuse or IDU) were at particularly high risk of death in both age
categories (Figure 2). Patients aged 40–69 years at study inclusion
with comorbidity also had substantially shorter survival (10-year
survival: 93% (95% CI: 89–97%)) than the comparison cohort
(adjusted MRR=5.5 (95% CI: 2.6–11.6)). The number of younger
patients with comorbidity and no substance abuse was so small
that no definite conclusions could be drawn. Presence of both
comorbidity and substance abuse was associated with a particu-
larly sinister prognosis among those aged 40–69 years, with an
estimated 10 year survival of 49% (95% CI: 22%–74%).
Importantly, mortality in patients aged 40–69 years without
comorbidity or substance abuse was comparable to that of the
comparison cohort, whereas younger patients without comorbidity
or substance abuse still had substantially higher mortality than the
comparison cohort (10-year survival: 93% versus 99%; adjusted
MRR=5.7 (95% CI: 2.3–14.0).
Cause-specific mortality
Specific causes of death are illustrated in Figure 3 and
Appendix 4. In patients aged 20–39 years with cleared HCV-
infection we observed 60 unnatural deaths with 32 of these being
categorised as ‘‘accidental poisoning by and exposure to noxious
substances’’ (ICD10: X40–X49). The 10-year risk of unnatural
death was 10% (95% CI: 7%–13%), the 10-year risk of non-liver-
related natural death was 2% (95% CI: 1%–3%) and the 10-year
risk of liver-related death was 1% (95% CI: 1%–3%). Even in
patients aged 20–39 without substance abuse or comorbidity, the
10-year risk of unnatural death was 4% (95% CI: 2%–9%)
(Figure 4). In patients with cleared HCV-infection aged 40–69
years, the 10-year risk of unnatural death was 7% (95% CI: 5%–
9%), the 10-year risk of non-liver-related natural death was 9%
(95% CI: 6%–13%) and the 10-year risk of liver-related death
was 4% (95% CI: 3%–6%).
Discussion
In this nationwide cohort study, we demonstrated that patients
with cleared HCV-infection suffer from a substantial risk of death,
by far exceeding that of individuals of the same age and sex from
the general population without comorbidity or substance abuse.
However, some subgroups of patients have a reasonable prognosis,
especially those aged 40–69 years without comorbidity or
substance abuse. Their 10-year survival was similar to that of
the comparison cohort. However, 50% of our study population
had substance abuse, either alone or in combination with
comorbidity, and they were at a substantially elevated risk of
death; 10-year survival in patients aged 40–69 with substance
abuse and comorbidity was approximately 49% (95% CI: 33%–
74%).
Cleared HCV-Infection and Mortality
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The main limitation of our study was its reliance on national
registries rather than clinical data to capture substance abuse and
comorbidities. Expert opinion and our own clinical experience
suggest that the majority of HCV-infected patients in Denmark
are IDUs [26]. However, national registry data indicated that only
47% of patients were IDUs. Thus some of the excess mortality in
patients aged 20–39 years who were not categorized as having
drug abuse could, in part, be explained by misclassification of
IDU. This suggestion is supported by the 4% 10-year risk of
unnatural death in patients aged 20–39 years without documented
substance abuse or comorbidity. Misclassification of IDU also may
affect those aged 40–69 years; however, we suspect that these
patients are more likely to be former IDUs, while younger patients
affected by misclassification are more likely to be current IDUs.
This difference could explain why patients aged 40–69 years
Table 1. Characteristics of the patients with cleared HCV-infection and the comparison cohort.
Total cohort 20–39 years at study inclusion 40–69 years at study inclusion
Cleared HCV
cohort
Comparison
cohort
Cleared HCV
cohort
Comparison
cohort
Cleared HCV
cohort
Comparison
cohort
N 2320 9280 1067 4268 1253 5012
Male, n (%) 1303 (56) 5212 (56) 602 (56) 2408 (56) 701 (56) 2804 (56)
Age, median (interquartile range) 41 (33–51) 41 (33–51) 32 (28–36) 32 (28–36) 50 (45–57) 50 (45–57)
Year of study inclusion, median
(interquartile range)
2002 (1999–2004) 2002 (1999–2004) 2001 (1999–2003) 2001 (1999–2003) 2002 (2000–2004) 2002 (2000–2004)
IDU, n (%) 1101 (47) 0 (0) 585 (55) 0 (0) 516 (41) 0 (0)
Alcohol abuse 266 (11) 0 (0) 77 (7) 0 (0) 189 (15) 0 (0)
CCI, n (%)
0 1956 (84) 0 (0) 974 (91) 0 (0) 982 (78) 0 (0)
1–2 315 (14) 0 (0) 85 (8) 0 (0) 230 (18) 0 (0)
3+ 49 (2) 0 (0) 8 (1)**** 0 (0) 41 (3)***** 0 (0)
Comorbidities in CCI*
Myocardial infarction 5 (0) 0 (0) 1 (0) 0 (0) 4 (0) 0 (0)
Congestive heart failure 8 (0) 0 (0) 0 (0) 0 (0) 8 (1) 0 (0)
Peripheral vascular disease 43 (2) 0 (0) 8 (1) 0 (0) 35 (3) 0 (0)
Cerebrovascular disease 26 (1) 0 (0) 9 (1) 0 (0) 17 (1) 0 (0)
Dementia 10 (0) 0 (0) 7 (1) 0 (0) 3 (0) 0 (0)
Chronic pulmonary disease 108 (5) 0 (0) 32 (3) 0 (0) 76 (6) 0 (0)
Connective tissue disease 31 (1) 0 (0) 3 (0) 0 (0) 28 (2) 0 (0)
Ulcer disease 79 (3) 0 (0) 12 (1) 0 (0) 67 (5) 0 (0)
Diabetes mellitus type 1 and 2 31 (1) 0 (0) 6 (1) 0 (0) 25 (2) 0 (0)
Hemiplegia 4 (0) 0 (0) 1 (0) 0 (0) 3 (0) 0 (0)
Moderate to severe renal disease 52 (2) 0 (0) 16 (1) 0 (0) 36 (3) 0 (0)
Diabetes mellitus type 1 and 2
with end organ damage
18 (1) 0 (0) 2 (0) 0 (0) 16 (1) 0 (0)
Any tumor 36 (2) 0 (0) 7 (1) 0 (0) 29 (2) 0 (0)
Leukemia 2 (0) 0 (0) 0 (0) 0 (0) 2 (0) 0 (0)
Lymphoma 10 (0) 0 (0) 4 (0) 0 (0) 6 (0) 0 (0)
Metastatic solid tumor 6 (0) 0 (0) 0 (0) 0 (0) 6 (0) 0 (0)
AIDS** 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Mild liver disease*** 316 (14) 0 (0) 100 (9) 0 (0) 216 (17) 0 (0)
Moderate to severe liver disease*** 51 (2) 0 (0) 13 (1) 0 (0) 38 (3) 0 (0)
Income (% of national average for the same age and gender), n (%)
0–49 1,020 (44) 1,343 (15) 553 (52) 857 (20) 467 (37) 486 (10)
50–99 889 (38) 4,028 (43) 371 (35) 1840 (43) 518 (41) 2188 (44)
100+ 441 (18) 3,909 (42) 143 (13) 1571 (37) 268 (21) 2338 (47)
*: patients could have more than one category of comorbidity, and therefore the sum of the comorbidity-categories is bigger than the sum of patients with
comorbidity.
**: Patients with HIV were excluded from the study.
***: The liver diseases of the CCI were not included in our comorbidity score, as they were considered being part of the causal pathway of mortality.
****: 9% (=8/(8+85)) of 20–39 year old patients with comorbidity.
*****: 15% (=41/(412230)) of 40–69 year old patients with comorbidity.
doi:10.1371/journal.pone.0022476.t001
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substantial increase in mortality, while those aged 20–39 years
without recorded substance abuse or comorbidity were at
increased risk of death. Another limitation of the registration of
IDU is that it does not allow us to distinguish former from current
users. Whereas the RDT in principle allows us to distinguish
between IDUs currently undergoing treatment from IDUs
previously having undergone treatment, it is impossible for us to
determine whether previously treated patients are reusing drugs,
and further we cannot preclude the possibility that IDUs currently
undergoing treatment are in fact also using drugs. There were also
limitations in our registration of alcohol abuse. We used the
Danish National Hospital Registry and thereby we missed cases of
alcohol abuse not leading to hospital contacts. Especially moderate
alcohol abuse thereby might have been unrecognized. Further, we
were unable to establish any dose-response relationship regarding
alcohol abuse, as the ICD8- and 10 codes used could not be
translated into any quantitative measure of alcohol abuse. Another
study limitation is lack of data on antiviral therapy. However, as
inclusion of patients depended on the first HCV RNA measure-
ment following the first positive HCV-antibody test, we find it
unlikely that a large proportion received antiviral therapy (as the
natural sequence leading to treatment normally would be positive
HCV antibodies followed by a positive HCV RNA test). Further,
median year of inclusion was 2002 when treatment activity was
still low in Denmark.
Discussion of our results and the literature
Several cohort studies, including our own, have found increased
mortality in HCV-infected patients [1–3]. This may be partly
explained by the effects of the viral infection [13,27–29] and partly
by socioeconomic risk factors and risk-taking behaviours [3,30–
32]. Our study extends earlier findings by identifying a subset of
patients with cleared HCV-infection, whose mortality is similar to
that of an age- and gender- matched comparison cohort with no
known risk factors (i.e., those aged 40–69 years without recorded
comorbidity or substance abuse). However, this subgroup
accounted for only a quarter of patients with cleared HCV-
infection; the remaining three-quarters had a substantially higher
risk than the comparison cohort. Our data therefore suggest that
serious attention should be paid to treating comorbidity and
substance abuse, in addition to optimal medical treatment of the
viral infection. Comorbidity and abuse had a substantial impact on
mortality in patients aged 40–69 years with a 10-year survival of
approximately 75% or below. This might be explained the high
proportion of patients with severe comorbidity and liver diseases in
this age group. In a Swiss cohort of 1,645 HCV-infected patients,
Prasad et al. found that individuals without cirrhosis, HIV- or
HBV-coinfection, alcohol abuse or IDU, who had a genotype
other than genotype 3, were not at substantially increased risk of
death compared to the general population (standardized mortality
ratio=1.14) [4]. However, as mortality in the general population
might be driven in part by alcohol abuse, the lack of an association
between HCV and mortality might be caused to some degree by
bias introduced by the prevalence of alcohol abuse in the general
population.
From a clinical vantage point, we extend the study by Prasad et
al. by providing absolute risk estimates stratified by age and risk
group, thus providing input for the clinical care of those who clear
the virus. Consistent with previous findings for HCV-infected
patients, individuals in our study had an increased risk of
unnatural death [1,3], especially in the younger age group, which
is likely to stem from their risk-taking behaviours [30,32]. Patients
with cleared HCV-infection also had an increased risk of liver-
related death. This could be explained by diagnostic bias in
patients referred for evaluation of liver disease, which could have
been caused by another agent (such as alcohol) and by evolution of
an adverse cirrhotic course despite clearance of the virus. The
Figure 1. Kaplan-Meier survival plot illustrating cumulative survival in patients with cleared HCV-infection and in an age- and
gender-matched comparison cohort without comorbidity, alcohol abuse or IDU, according to age at study inclusion. Solid line:
Patients with cleared HCV-infection; broken line: Individuals from the comparison cohort. The left-hand graph illustrates survival among individuals
aged 20–39 years at study inclusion. The right-hand graph illustrates survival in those aged 40–69 years at study inclusion.
doi:10.1371/journal.pone.0022476.g001
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PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e22476finding of an increased risk of non-liver-related natural deaths in
patients with cleared HCV-infection is probably due to the
presence of comorbidity in this group.
We conclude that a minority of HCV-infected patients who
clear the virus (those aged 40–69 with no comorbidity or substance
abuse) has a mortality rate comparable to individuals without
HCV (or comorbidity or substance abuse). However, most patients
have an elevated mortality rate despite clearance of the virus.
While viral clearance is an essential part of HCV management,
our study highlights the importance of also focusing other
conditions, such as alcohol abuse, IDU and comorbidity, which
might increase mortality.
Supporting Information
Appendix S1 Definitions of alcohol abuse, IDU and HIV
infection.
(DOC)
Appendix S2 ICD-10 codes for specific causes of death.
(DOC)
Figure 2. Kaplan-Meier survival plots illustrating cumulative survival in patients with cleared HCV-infection and in an age- and
gender-matched comparison cohort without comorbidity, alcohol abuse or IDU, according to patient characteristics and age at
study inclusion. Solid line: Patients with cleared HCV-infection; broken line: Individuals from the comparison cohort. The left-hand graphs illustrate
survival in individuals aged 20–39 years at study inclusion; the right-hand graphs illustrate survival in those aged 40–69 years at inclusion. Top row:
Patients with no substance abuse (alcohol abuse or IDU) or comorbidity; second row: patients with substance abuse; third row: patients with
comorbidity; and last row: patients with substance abuse and comorbidity.
doi:10.1371/journal.pone.0022476.g002
Figure 3. Cumulative incidence function illustrating cause-specific mortality in patients with cleared HCV-infection and an age- and
gender-matched comparison cohort without comorbidity, alcohol abuse or IDU, according to age at study inclusion. Solid line:
Patients with cleared HCV-infection; broken line: Individuals from the comparison cohort. The left-hand graph illustrates survival in individuals aged
20–39 years at study inclusion; the right-hand graph illustrates survival in those aged 40–69 years at inclusion.
doi:10.1371/journal.pone.0022476.g003
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Figure 4. Cumulative incidence function illustrating cause-specific mortality in patients with cleared HCV-infection without
comorbidity, alcohol abuse or IDU and an age- and gender-matched comparison cohort without comorbidity, alcohol abuse or
IDU, according to age at study inclusion. Solid line: Patients with cleared HCV-infection; broken line: Individuals from the comparison cohort.
Left- hand graph illustrates survival in individuals aged 20–39 years at study inclusion; right-hand graph illustrates survival in those aged 40–69 years
at inclusion.
doi:10.1371/journal.pone.0022476.g004
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